沙美特罗替卡松粉吸入剂治疗咳嗽变异型哮喘43例临床观察  

Salmeterol/Fluticasone Powder Inhalation for Patients with Cough-Variant Asthma: Clinical Observation on 43 Cases

作　　者：孟凡信[1] 李金明[1] 

机构地区：[1]山东省临沂市人民医院,临沂市276000

出　　处：《中国医院用药评价与分析》2008年第8期619-621,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的：观察沙美特罗替卡松粉吸入剂治疗咳嗽变异型哮喘（CVA）的临床疗效和安全性。方法：将85例符合诊断的咳嗽变异型哮喘患者,随机分为治疗组43例,对照组42例。治疗组予以沙美特罗替卡松粉吸入剂,每日2次,早晚各吸入1次;对照组予以班布特罗胶囊10 mg晚服,布地耐德干粉吸入剂每日600μg吸入。两组均4周为1疗程,治疗2-3疗程,观察并记录治疗前后临床的症状、体征变化及不良反应。结果：治疗组患者临床症状及疗效明显改善,与对照组比较有显著性差异（P〈0.05）。结论：沙美特罗替卡松粉吸入对咳嗽变异型哮喘病人临床症状缓解及降低气道高反应性疗效肯定,值得临床推广应用。OBJECTIVE： To evaluate the clinical efficacy and safety of salmeterol/fluticasone powder inhalation in patients with cough-variant asthma （VCA）. METHODS： 85 VCA patients were randomly assigned to receive salmeterol/ fluticasone powder inhalation 300ug n＆m （trial group, n = 43 ）or budesonide dry powder inhalation 600ug daily plus oral Bambuterol capsule 10mg qd every evening （Control Group, n = 42）for 2 - 3 courses （4 weeks/cycle）. The clinical efficacy and toxicity in two groups were monitored and compared. RESULTS： The clinical symptoms and curative efficacy in the Trial Group improved significantly, and the difference was significant as compared with the Control Group （P 〈 0.05 ）. CONCLUSION： Salmeterol/fluticasone powder inhalation deserved to be popularized in the clinic for it has confirmed efficacy in relieving clinical symptoms and lowering airway hyperreactivity in patients with VCA.

关 键 词：咳嗽 哮喘 沙美特罗替卡松 

分 类 号：R974[医药卫生—药品]